Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Want to cut your energy bills? Here’s how five experts are doing it 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilar Insulin Market Access" report to their offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations.
As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
1. EXECUTIVE SUMMARY
2. US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
3. FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
4. METHODOLOGY
For more information about this report visit http://www.researchandmarkets.com/research/5k4v4m/biosimilar
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
